

1 April 2025

Quadrise Plc
("Quadrise", "QED" or the "Company")

Signature of MAC² Services Supply Agreement

Quadrise Plc (AIM: QED), the supplier of innovative energy solutions for a cleaner planet, is pleased to announce the signature of a Services Supply Agreement ("**Agreement**") with MAC² Solutions NV ("**MAC²**") with regard to the production of MSAR® and bioMSAR™ fuels for the Company's forthcoming marine vessel trials on board the MSC Leandra V, expected to commence in Q2 2025 (the "**Trials**").

The Trials will comprise an initial Proof of Concept period using MSAR® and then bioMSAR™ for performance baseline tests, followed by 4,000 hours of operation (approximately 6-8 months) on bioMSAR™ in order to obtain a letter of no objection from engine manufacturer Wärtsilä upon success.

The Agreement sets out the responsibilities of Quadrise and MAC² in respect of the Trials, which will be carried out following the installation and commissioning of Quadrise equipment at the MAC² facility in Antwerp, Belgium in Q2 2025. MAC² will be responsible for the supply of jetty space, utilities, permits and ad-hoc support services during the Trials, whilst Quadrise will be responsible for the provision of MSAR® and bioMSAR™ technology and fuel production equipment and personnel.

The remaining bilateral agreements to facilitate the Trials, including a toll manufacturing agreement between Cargill BV ("Cargill") and Quadrise in respect of fuel manufacture, continue to be advanced and further announcements will be made in due course.

Alongside the Trials, the parties plan to initiate commercial MSAR® and bioMSAR™ bunker supply operations to the marine sector through the MAC² facilities in the Port of Antwerp-Bruges to MSC and other shipping companies on a permanent basis.

Commenting on the update, Jason Miles, Chief Executive Officer of Quadrise, said:

"We are pleased to have signed this services agreement with MAC² to progress our plans for supplying MSAR® and bioMSAR™ to the marine sector from Antwerp-Bruges. We look forward to working with them as we prepare for the trials on the MSC Leandra V in Q2 2025 and to a successful longer-term partnership as we progress to commercial supply."

For additional information, please contact:

Quadrise Plc

+44 (0)20 7031 7321

Andy Morrison, Chairman
Jason Miles, Chief Executive Officer

Nominated Adviser

Cavendish Capital Markets Limited

+44 (0)20 7220 0500

Ben Jeynes
Katy Birkin
George Lawson

Joint Brokers

Shore Capital Stockbrokers Limited

+44 (0)20 7408 4090

Toby Gibbs (Corporate Advisory)
Fiona Conroy (Corporate Broking)

VSA Capital Limited

+44 (0)20 3005 5000

Andrew Raca (Corporate Finance)
Andrew Monk (Corporate Broking)

Public & Investor Relations

BLUE Communications Limited

Rhys Thomas
Sam Deacon

+44 (0) 7595 227750

+44 (0)7527 558846

About Quadrise

Quadrise is the supplier of MSAR® and bioMSAR™ emulsion technology, fuels and biofuels, providing innovative solutions to reduce energy costs and greenhouse gas emissions today for clients in the global power generation, shipping, industrial and refining industries.

Learn more at: www.quadrise.com

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR") and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

AGRDFLFXEXLEBBX